
In a report released on November 11, Naz Rahman from Maxim Group maintained a Buy rating on Palisade Bio, with a price target of $8.00. Naz Rahman’s rating is based
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| PALI | Palisade Bio | 0.95 | -1.00 | -51.21% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.95 | -51.21% |

In a report released on November 11, Naz Rahman from Maxim Group maintained a Buy rating on Palisade Bio, with a price target of $8.00. Naz Rahman’s rating is based

Piper Sandler analyst Yasmeen Rahimi lowered the firm’s price target on Palisade Bio (PALI) to $16 from $25 and keeps an Overweight rating on the shares. The firm notes the

H.C. Wainwright lowered the firm’s price target on Palisade Bio (PALI) to $5 from $7 and keeps a Buy rating on the shares. The company remains funded through two Phase

As of September 30, 2026, the Company had $113.6M in cash and cash equivalents, which the Company believes will fund operations through key Phase 2 clinical milestones, including the anticipated

H.C. Wainwright analyst Mitchell Kapoor has reiterated their bullish stance on PALI stock, giving a Buy rating on October 21. Mitchell Kapoor has given his Buy rating due to a

Palisade Bio (PALI) announced that the first patient has been dosed in ASCENTRA-UC, its global Phase 2b clinical trial evaluating PALI-2108 in approximately 204 patients with moderately to severely active

Palisade Bio, Inc. ($PALI) announced an update on their ongoing clinical study. The ASCENTRA-UC study is a phase 2 trial run by Palisade Bio, Inc. It tests PALI-2108 as an

Palisade Bio (PALI) announced clinical and translational findings presented in one oral presentation and three moderated posters at United European Gastroenterology, or UEG, Week 2026, held October 17-20 in Barcelona,

Palisade Bio, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on the stock and has a

Raymond James analyst Thomas Deal initiated coverage of Palisade Bio (PALI) with an Outperform rating and $6 price target Palisade is developing PALI-2108 for inflammatory bowel disease, including ulcerative colitis
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 12, 2026 | ||||
| buy | Reiterated | Nov 12, 2026 | ||||
| buy | Reiterated | Nov 11, 2026 | ||||
| buy | Reiterated | Nov 11, 2026 | ||||
| buy | Reiterated | Nov 11, 2026 | ||||
| buy | Initiated | Oct 8, 2026 | ||||
| buy | Reiterated | Jul 6, 2026 | ||||
| buy | Initiated | Apr 8, 2026 | ||||
| buy | Reiterated | Mar 31, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| May 7, 2027TBA | $181.07M | ― | ― | 0.08 | -4.54 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.